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Abstract: Selective FGFR inhibitors such as infigratinib (BGJ398) and erdafitinib (JNJ-42756493) have
been evaluated in clinical trials for cancers with FGFR3 molecular alterations, particularly in urothelial
carcinoma patients. However, a substantial proportion of these patients (up to 50%) display intrinsic
resistance to these drugs and receive minimal clinical benefit. There is thus an unmet need for
alternative therapeutic strategies to overcome primary resistance to selective FGFR inhibitors. In this
study, we demonstrate that cells expressing cancer-associated activating FGFR3 mutants and the
FGFR3-TACC3 fusion showed primary resistance to infigratinib in long-term colony formation assays
in both NIH-3T3 and urothelial carcinoma models. We find that expression of these FGFR3 molecular
alterations resulted in elevated constitutive Src activation compared to wildtype FGFR3 and that
cells co-opted this pathway as a means to achieve intrinsic resistance to infigratinib. Targeting the
Src pathway with low doses of the kinase inhibitor dasatinib synergistically sensitized multiple
urothelial carcinoma lines harbouring endogenous FGFR3 alterations to infigratinib. Our data provide
preclinical rationale that supports the use of dasatinib in combination with selective FGFR inhibitors
as a means to overcome intrinsic drug resistance in the salvage therapy setting in urothelial cancer
patients with FGFR3 molecular alterations
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1. Introduction
Activating molecular alterations in the Fibroblast Growth Factor Receptor 3 (FGFR3) gene have
been identified through large-scale next generation genomic sequencing efforts across a range of
tumour types including urothelial carcinoma, lung squamous cell carcinoma, glioblastoma and
myeloma [1–4]. These molecular alterations primarily comprise of point mutations that span across
the gene (e.g., S249C, R248C and K652E) and gene fusions (e.g., FGFR3-TACC3 fusion). The cancer
type with the highest proportion of FGFR3 alterations is urothelial carcinoma with a frequency of
60–80% in the non-muscle-invasive form and 15–20% in the muscle-invasive form harbouring these
molecular aberrations [3,5–7]. The most common FGFR3 point mutation found across cancer types is
S249C in which the extracellular domain cysteine substitution leads to the formation of a disulphide
bond between receptor monomers resulting in ligand-independent constitutive dimerization and
activation [2,8–10]. In contrast, the FGFR3-TACC3 fusion has been described at low frequencies
(2–8%) in urothelial cancers and glioblastoma and mediates it oncogenic activity through constitutive
dimerization of FGFR3 driven by TACC3 [1,2,4,11,12].
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The identification of these FGFR3 aberrations in cancer has led to the clinical evaluation of
selective Fibroblast Growth Factor Receptor (FGFR) small molecule tyrosine kinase inhibitors (TKIs)
in this molecularly defined subset of patients. The most advanced candidates include erdafitinib
(JNJ-42756493) and infigratinib (BGJ398). Pal et al., reported response rates of 25.4% in the evaluation
of infigratinib in 67 patients with previously treated advanced urothelial carcinoma with FGFR3
alterations [13]. Similarly, the BLC2001 phase II single-arm trial of erdafitinib in FGFR-altered urothelial
carcinomas showed clinical responses in 40% of patients [14]. This result has led to the accelerated
approval of erdafitinib in 2019 by the US Food and Drug Administration (FDA) for locally advanced
or metastatic urothelial carcinomas with FGFR2 and FGFR3 alterations. Despite these promising
results, the BLC2001 trial showed that only 49% and 16% of patients with FGFR point mutations and
fusions, respectively, achieved disease response with erdafitinib. Similarly, Pal et al., reported that only
42.9% of patients with documented FGFR3 activating point mutations responded to infigratinib [13,14].
These results indicate that notwithstanding the presence of a FGFR3 molecular alteration, there remains
a significant proportion of patients that harbour intrinsic resistance to selective FGFR TKIs and do not
respond to these agents. For these patients, there are limited therapeutic alternatives available and
there is thus an urgent unmet need to identify effective ways to overcome primary resistance.
In this study, we show that cells expressing a subset of activating FGFR3 mutants and the
FGFR3-TACC3 fusion are intrinsically resistant to selective FGFR TKI inhibition in long-term assays.
We further demonstrate that expression of these FGFR3 mutants and FGFR3-TACC3 results in elevated
constitutive Src activation levels compared to wildtype (WT) FGFR3, which can be exploited for therapy
with the multi-target TKI dasatinib. We find that targeting the Src pathway with low dose dasatinib
sensitizes urothelial carcinoma cell lines harbouring endogenous FGFR3 molecular alterations to
selective FGFR TKIs including infigratinib. Our preclinical data suggest that patients with FGFR3
molecular alterations may benefit from treatment with FGFR and Src inhibitors in combination,
which can overcome intrinsic resistance associated with selective FGFR TKI monotherapy.
2. Results
2.1. FGFR3-TACC3 Gene Fusion and Activating FGFR3 Point Mutants are Intrinsically Resistant to
Infigratinib in the NIH-3T3 Cell Line Model
We first evaluated the effects of infigratinib in NIH-3T3 cells expressing a selection of the most
prevalent activating FGFR3 molecular alterations in cancer. These included the most common FGFR3
fusion (FGFR3-TACC3) and extracellular domain (S249C) and kinase domain (K652E) point mutations.
In addition, we examined N542K, which has previously been described as a congenital mutation in
hypochondroplasia [15], due to its reported high kinase activity in in vitro assays [16]. Expression of
the FGFR3-TACC3 gene fusion and FGFR3 mutations S249C, N542K and K652E led to constitutive
phosphorylation of Src when compared to the WT FGFR3 control with no differences observed in
Erk1/2 and AKT phosphorylation levels (Figure 1A). Consistent with previous reports, the transforming
potential of these FGFR3 aberrations was demonstrated by an increase in the ability to grow under
anchorage-independent conditions versus WT FGFR3 (Figure 1B,C) [16–18]. Short-term (72 h) cell
viability experiments found that as previously shown [16,19–21], cells expressing FGFR3-TACC3
and the three FGFR3 mutants were sensitive to treatment with infigratinib with IC50 values in the
nanomolar range (Figure 1D,E). It has been demonstrated that FGFR3 inhibition with FGFR inhibitors
leads to selective downregulation of the Erk1/2 pathway [21–23]. We show that unlike the WT FGFR3
cells, treatment with infigratinib decreased phosphoErk1/2 levels in the three mutant FGFR3 lines and
abolished Erk1/2 phosphorylation in a dose-dependent manner in the FGFR3-TACC3 cells, confirming
that this pathway is a direct downstream target of the FGFR3 mutants and FGFR3-TACC3 fusion
(Figure 1F). Interestingly, although constitutive activation of Src was associated with the expression of
the FGFR3 mutants and FGFR3-TACC3 fusion in the NIH-3T3 cells (Figure 1A), the phosphorylation
levels of Src were not downregulated upon FGFR3 kinase inhibition by infigratinib (Figure 1F).
Further assessment of the efficacy of infigratinib in long-term (2 weeks) colony formation assays
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finds that despite the potent effects of this drug in the FGFR3 mutant and fusion expressing cells in
short-term cell viability assays, there was an unexpected observation of a high number of resistant
colonies persisting after 2 weeks of drug treatment (Figure 1G,H). At 1 µM drug treatment, there
was no significant decrease in colony formation in any of the FGFR3 point mutant expressing cells,
with only a small decrease (~20%) in the FGFR3-TACC3 expressing cells (Figure 1H). Importantly,
these intrinsic resistant colonies persist even at very high infigratinib doses of 2 µM which models the
primary resistance observed in a subset of patients in clinical trials.
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Figure 1. Cells bearing FGFR3 molecular alterations harbour intrinsic resistance to infigratinib. (A) 
Immunoblot of downstream cellular signalling pathways upon expression of FGFR3 constructs in 
NIH-3T3 cells is shown. (B) Representative images of the panel of NIH-3T3 cells in anchorage-
independent soft agar assays. (C) Bar plots showing the quantification of well coverage of soft agar 
assay in panel B (n = 6). Statistical analysis of FGFR3 mutants and fusion versus WT FGFR3 was 
performed by one-way ANOVA with Dunnett’s post-hoc multiple comparison adjusted p-value (** p 
< 0.01). (D) Dose-response curves of the panel of NIH-3T3 cell lines upon treatment with infigratinib 
for 72 h. Cell viability is normalised to DMSO control treatment (n = 3). (E) Bar plots showing IC50 
values of infigratinib calculated from dose response curves in (D). Statistical analysis of FGFR3 
mutations and fusion versus WT FGFR3 was performed by one-way ANOVA with Dunnett’s post-
hoc multiple comparison adjusted p-value (*** p < 0.001). (F) Immunoblot of Erk1/2 and Src 
phosphorylation levels in NIH-3T3 cells treated with infigratinib at the indicated doses for 6 h is 
shown. (G) Representative images of long term colony formation assay in the NIH-3T3 cell line panel 
Figure 1. Cells bearing FGFR3 molecular lterations harbour intrinsic resistance to infigratinib.
(A) Immunoblot of downstream cellular signalling pathways upon expression of FGFR3 constructs
in NIH-3T3 cells is shown. (B) Representative images of the panel of NIH-3T3 cells in
anchorage-independent soft agar a says. (C) Bar plots showing the quantification of ell coverage
of soft agar assay in panel B (n = 6). Statistical analysis of FGFR3 mutants and fusion versus WT
FGFR3 was performed by one-way ANOVA with Dunnett’s post-hoc multiple comparison adjusted
p-value (** p < 0.01). (D) Dose-response curves of the panel of NIH-3T3 cell line upon treatment with
infigratinib for 72 h. Cell viability is normalised to DMSO control treatment (n = 3). (E) Bar plots
showing IC50 values of infigratinib calculated from dose response curves in (D). Statistical analysis of
FGFR3 mutations and fusion versus WT FGFR3 was performed by one-way ANOVA with Dunnett’s
post-hoc multiple comparison adjusted p-value (*** p < 0.001). (F) Immunoblot of Erk1/2 and Src
phosphorylation levels in NIH-3T3 cells treated with infigratinib at the indicated doses for 6 h is shown.
(G) Representative images of long term colony formation assay in the NIH-3T3 cell line panel upon
treatment with infigratinib or DMSO control at the indicated doses for 2 weeks. (H) Bar plots showing
the quantification of well coverage of the colony formation assay in panel G. Data for each cell line are
normalised to DMSO control treatment (n = 3). Statistical analysis of drug treatment versus DMSO was
performed by paired two-way ANOVA with Dunnett’s post-hoc multiple comparison adjusted p-value
(* p < 0.05, *** p < 0.001). Data presented for (C), (D), (E) and (H) represent mean ± SD. EV – empty
vector control, WT – wildtype FGFR3, F3-TACC3 – FGFR3-TACC3.
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2.2. FGFR3-TACC3 and S249C Expression Confers Resistance to Dasatinib
To interrogate the key signalling dependencies in the panel of FGFR3 expressing NIH-3T3 cells, a
targeted small molecule inhibitor screen was undertaken. This screen was comprised of 32 small molecule
inhibitors that target major kinase and non-kinase oncogenic signalling pathways in cells. These inhibitors
include broad-spectrum kinase inhibitors such as imatinib, dasatinib and foretinib as well as selective
kinase inhibitors such as infigratinib (FGFR), binimetinib (MEK), AZD5363 (AKT), BEZ235 (PI3K/mTOR)
and MK8776 (CHK1). The screen also has a small number of non-kinase inhibitors including NVP-AUY922
(HSP90), GSK126 (enhancer of zeste homolog 2 (EZH2)) and JQ1 (bromodomain and extra-terminal (BET))
(See Table S1 for list of compounds used in the screen and key targets).
As a positive control for the assay, we show that as expected, FGFR3 point mutant and fusion
expressing cells were sensitive to both multi-target (ponatinib, foretinib, lenvatinib, cediranib) and
selective (infigratinib and AZD4546) FGFR TKIs (Figure 2A). Interestingly, the expression of some FGFR3
molecular alterations conferred a survival advantage (of > 1.2 fold) to a small number of compounds
compared to WT FGFR3. These included BEZ235 (N542K and K652E), JQ1 (FGFR-TACC3, S249C and
K652E), MK8776 (S249C) and dasatinib (FGFR3-TACC3 and S249C). Given that the expression of FGFR3
molecular alterations led to the constitutive activation of Src (Figure 1A), dasatinib, a broad-spectrum
TKI that potently inhibits Src as one of its targets [24,25], was taken forward for further investigation.
Full dose response assessment of dasatinib in short-term viability assays showed that
FGFR3-TACC3 and S249C conferred resistance to this drug with an IC50 of 3–4 µM compared
to the WT FGFR3 and the N542K and K652E mutations (<1 µM) (Figure 2B,C). These results were
recapitulated in the long-term colony formation assays with the FGFR3-TACC3 and S249C expressing
cells showing high levels of resistant colonies in the presence of dasatinib compared to the other cell
lines in the panel (Figure 2D,E). Evaluation of downstream signalling pathways by immunoblotting
confirmed that dasatinib treatment led to a dose dependent decrease in Src phosphorylation levels
across the cell line panel (Figure 2F).
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Figure 2. Cells expressing FGFR3-TACC3 and FGFR3 S249C mutant are resistant to dasatinib as a single
agent. (A) Heatmap d picting one-way hier rchical clustering of cell vi bility d ta in the t rgeted drug
screen. FGFR3 expressing NIH-3T3 cells were seeded in 96 well plates and viability measured using
CTG assay following 72 h treatment with small mole u e inhibitors at 500 nM (50 nM for NVP-AUY922).
Cell viability data is normalised to DMSO control for each cell line and represented as a heatmap
relative to WT FGFR3 cells (n = 3). (B) D se-response curves of the panel of NIH-3T3 c ll lin s upon
treatment with dasatinib for 72 h. Cell viability is normalised to DMSO control treatment (n = 3). (C) Bar
plots showing IC50 values of dasatinib calculated from dose response curves in (B). Statistical analysis
of FGFR3 mutations and fusion versus WT FGFR3 was performed by one-way ANOVA with Dunnett’s
post-hoc multiple comparison adjusted p-value (* p < 0.05). (D) Representative images of long term
colony formation assay in the NIH-3T3 cell line panel upon treatment with dasatinib or DMSO control
at the indicated doses for 2 weeks. (E) Bar plots showing the quantification of well coverage of the
colony formation assay in panel D. Data for each cell line is normalised to DMSO control treatment
(n = 3). Statistical analysis of drug treatment versus DMSO was performed by two-way ANOVA with
Dunnett’s post-hoc multiple comparison adjusted p-value (** p < 0.01, *** p < 0.001). (F) Immunoblot of
Erk1/2 and Src phosphorylation levels in NIH-3T3 cells treated with dasatinib at the indicated doses for
6 h is shown. Data presented for (B), (C) and (E) represent mean ± SD. EV – empty vector control, WT –
wildtype FGFR3, F3-TACC3 – FGFR3-TACC3.
We hypothesized that the constitutive dimerization in these FGFR3 molecular alterations may
be responsible for the observed resistance to dasatinib. Since disruption of the FGFR3-TACC3 fusion
through genetic means is non-trivial, we focused our efforts on the S249C point mutation. It has
previously been demonstrated that the cysteine substitution in S249 within the extracellular domain
of FGFR3 leads to constitutive receptor dimerization and activation through the formation of an
intermolecular disulphide bond [2,8–10]. To investigate the role of this cysteine residue in driving
resistance to dasatinib, we engineere NIH-3T3 cell lines expressing an FGFR3 mutant where the
cysteine has been substituted to an alanine residue (S249A). Evaluation in non-reducing PAGE showed
that the alanine substitution led to the loss of constitutive FGFR3 dimers both in th presence and
abs nce f infigratinib (Figure S1A). While cells expressing S249C were resistant to dasatinib in
bot short-t rm viability assays and ong-term col ny formation assays, the substitution to alanine
resulted in pronounced sensitivity to this drug with levels comparable to WT FGFR3 expressing cells
(Figure S1B–D). Similar results were seen in cells engineered to express another common FGFR3
cysteine mutant found in urothelial carcinoma (R248C) and its glycine substituted mutant (R248G)
(Figure S1E,F). Taken together, our data demonstrate that while treatment with dasatinib resulted in a
decrease in Src phosphorylation levels in all FGFR3 expressing cell lines examined, the expression
of FGFR3-TACC3 and S249C unexpectedly confers resistance to this drug. Furthermore, we show
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that in two of the most common FGFR3 extracellular cysteine mutants in urothelial carcinoma (S249C
and R248C), the constitutive receptor dimerization mediated by the cysteine residue is necessary for
driving dasatinib resistance.
2.3. Dasatinib Sensitizes NIH-3T3 Cells with FGFR3 Molecular Alterations to Infigratinib Treatment
The use of combination therapy as a means to suppress multiple signalling pathways to overcome
drug resistance is a well-established concept in cancer biology [26,27]. Given that infigratinib and
dasatinib act through parallel signalling pathways of Erk1/2 and Src respectively (Figure 1F and 2F), we
posited that the addition of dasatinib may enhance the activity of infigratinib through the dampening
of the Src pathway to overcome the intrinsic resistance observed in long-term colony formation assays
(Figure 1G). Co-treatment of infigratinib with low dose (100–200 nM) of dasatinib resulted in an almost
complete elimination of the resistant colonies that were previously observed in the treatment with
single agent infigratinib or dasatinib (Figure 3A,B). Notably, this effect appeared to be more potent in
cells expressing FGFR3-TACC3 and the FGFR3 point mutants with some resistant colonies remaining
in the WT FGFR3 expressing cells even at high drug doses (Figure 3B). This result was recapitulated in
the short-term cell viability assays with the FGFR3-TACC3 and S249C expressing cells having a more
pronounced sensitivity to the combination than WT FGFR3 expressing cells (Figure 3C).
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plots showing the quantification of well coverage of the colony formation assay in panel A. Data for 
each cell line are normalised to DMSO control treatment (n = 3). Statistical analysis of drug treatment 
versus DMSO was performed by two-way ANOVA with Dunnett’s post-hoc multiple comparison 
adjusted p-value (*** p < 0.001). (C) Dose-response curves of the WT FGFR3, FGFR3-TACC3 and S249C 
Figure 3. Combination of dasatinib and infigratinib overcomes intrinsic resistance. (A) Representative
images of long term colony formation assay in the NIH-3T3 cell line panel upon treatment with a
combination of dasatinib and infigratinib or DMS control at the indicated doses for 2 weeks. (B) Bar
plots showing the quantificat on f well covera the colony formation assay in panel A. Data for
each cell line are normalised to DMSO control treat t (n = 3). Statistical analysis of drug treatment
versus DMSO was performed by two-way ANOVA with Dunnett’s post-hoc multiple comparison
adjusted p-value (*** p < 0.001). (C) Dose-response curves of the WT FGFR3, FGFR3-TACC3 and S249C
cell lines upon treatment with infigratinib and dasatinib either as single agents or in combination for
72 h. For the combination arm, cells were treated with infigratinib and dasatinib in a 1:1 ratio with
each drug at half the dose of the single agent. Cell viability is normalised to DMSO control treatment
(n = 3). Statistical analysis of the combination arm versus either single agent at each dose was evaluated
using two-way ANOVA with Dunnett’s post-hoc multiple comparison adjusted p-value at each drug
dose (** p < 0.01, *** p < 0.001). (D) Immunoblot of Erk1/2 and Src phosphorylation levels in NIH-3T3
cells treated with a combination of infigratinib and dasatinib in a 1:1 ratio for 6 h, with the indicated
concentration representing to total drug concentration used. Data presented for (B) and (C) represent
mean ± SD. EV – empty vector control, WT – wildtype FGFR3, F3-TACC3 – FGFR3-TACC3, Inf –
infigratinib, Das – dasatinib.
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To evaluate the signalling consequence of combination therapy with infigratinib and dasatinib,
an assessment of Erk1/2 and Src activation levels after treatment with both drugs was performed
by immunoblotting. As expected, cells bearing FGFR3-TACC3, S294C, N542K and K652E showed a
decrease in the phosphorylation levels of both Src and Erk1/2 upon treatment with the combination,
which is the result of the independent effects of dasatinib and infigratinib on these pathways respectively
as single agents (Figure 3D). In the S249C and K652E expressing cells, there was a more potent inhibition
of phosphoErk1/2 in the drug combination compared to single agent treatment with infigratinib alone
(Figure 1F), suggesting that in a subset of FGFR3 mutants, dasatinib may enhance the effects of
infigratinib by increased suppression of the Erk1/2 pathway.
2.4. Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancer Cell
Lines with FGFR3 Molecular Alterations
We sought to establish if the drug responses observed in the NIH-3T3 model system is also present
in cancer cell lines harbouring endogenous FGFR3 molecular alterations. To that end, we evaluated
the effects of two structurally unrelated selective FGFR inhibitors (infigratinib and PD173074) and
dasatinib as single agents or in combination in a panel of urothelial cancer cell lines. The panel included
RT112M (FGFR3-TACC3) and 639V (R248C) as well as BFTC905 which expresses WT FGFR3 and was
used as a control [28–30]. Long-term colony formation assays show that in line with previous reports,
RT112M was partially sensitive to infigratinib and PD173074 as single agents compared to BFTC905 and
639V (Figure 4A) [22]. It should be noted that despite the comparatively higher sensitivity observed
in the RT112M cells, there were still a large proportion of residual colonies upon drug treatment,
indicating that a significant fraction of cells displayed intrinsic resistance to selective FGFR inhibitors.
As observed in the NIH-3T3 panel, WT FGFR3 expressing BFTC905 cells were sensitive to dasatinib
treatment as a single agent while RT112M and 639V cells with FGFR3 molecular alterations were
partially resistant to this drug. The addition of dasatinib at low dose enhanced the efficacy of both
selective FGFR inhibitors in the RT112M and 639V cells resulting in a decrease in colony formation in
the combination arm compared to single agent FGFR inhibitor treatment (Figure 4A,B). We further
evaluated if the dasatinib and infigratinib combination was synergistic in dose response cell viability
assays (Figure 4C). Assessment of the combination index (CI) showed that the combination of dasatinib
and infigratinib led to a synergistic decrease in the cell viability (CI < 1) in the RT112M and 639V cells
across all drug doses tested up to 1 µM (Figure 4D).
To assess the signalling alterations associated with the observed phenotypes in the urothelial
cancer cell lines upon drug treatment, immunoblotting of Erk1/2 and Src phosphorylation levels was
undertaken. Infigratinib and PD173074 treatment did not affect phosphoErk1/2 levels in the BFTC905
and 639V cells but abolished phosphoErk1/2 levels in the RT112M cell line (Figure 4E). Dasatinib
treatment suppressed Src phosphorylation in all three cell lines which was accompanied by an increase
of total Src levels. As observed in the NIH-3T3 cells, the combination of a selective FGFR inhibitor with
dasatinib led to a reduction in the phosphorylation levels of both Erk1/2 and Src in the two cell lines
harbouring FGFR3 molecular alterations, RT112M and 639V. The Epidermal Growth Factor Receptor
(EGFR) has previously been shown to be a compensatory bypass mechanism which confers intrinsic
resistance to PD173074 treatment in the RT112M cell line [22]. Since Src is known to be regulated by
EGFR, we set out to ascertain if the observed Src phosphorylation in the urothelial cancer cell lines is
influenced by EGFR activity. Treatment of the cell line panel with the EGFR inhibitor gefitinib either
as a single agent or in combination with the selective FGFR inhibitors did not lead to a reduction in
Src phosphorylation levels (Figure S2A), confirming that Src is not an effector of EGFR activation but
rather a parallel resistance pathway in urothelial cancer cell lines.
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Figure 4. Targeting the Src pathway enhances the efficacy of selective FGFR inhibitors in urothelial
cancer cell lines with FGFR3 molecular alterations. (A) Representative images of long term colony
formation assay in urothelial cancer cell line panel upon treatment with infigratinib, PD173074, dasatinib
as single agent or in combination as well as DMSO control at the indicated doses for 2 weeks. (B) Bar
plots showing the quantification of well coverage of the colony formation assay in panel A. Data for each
cell line are normalised to DMSO control treatment (n = 3). Statistical analysis of drug treatment versus
DMSO was performed by two-way ANOVA with Dunnett’s post-hoc multiple comparison adjusted
p-value (*** p < 0.001). (C) Dose-response curves of the urothelial cancer cell lines upon treatment with
infigratinib and dasatinib either as single agents or in combination for 72 h. For the combination arm,
cells were treated with infigratinib and dasatinib in a 1:1 ratio with each drug at half the dose of the
single agent. Cell viability is normalised to DMSO control treatment (n = 3). Statistical analysis of the
combination arm versus either single agent at each dose was evaluated using two-way ANOVA with
Dunnett’s post-hoc multiple comparison adjusted p-value at each drug dose (** p < 0.01, *** p < 0.001).
(D) Combination index (CI) measurements for infigratinib and dasatinib in urothelial cancer cell lines
based on dose response data in pa el C. Synergy (CI < 1) in RT112M and 639V is shown across all
doses te ted up to 1 µM. (E) Immunoblot of Erk1/2 and Src phosph rylation levels in urothelial cancer
cells treated with single agent el ctive FGFR inhibitor or dasatinib and in combination for 1 h. The
combination arm was administered in a 1:1 ratio, with the indicated concentration representing the
total drug concentratio used. Da p esented for (B) and (C) repres nt mean ± SD. Inf – infigrati ib,
PD – PD173074, Das – d satinib.
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Given that dasatinib is a broad spectrum kinase inhibitor that blocks multiple kinases including
Src [24,25], we sought to demonstrate that Src is the primary target of this drug and the causative driver
of the observed intrinsic resistance to selective FGFR inhibitors. Specifically, we evaluated the ability
of the gatekeeper mutation in the avian Src gene (T338I), which blocks dasatinib binding to its kinase
domain, to rescue the phenotypic effects of dasatinib [31]. As a comparator, the WT Src gene and
an empty vector (EV) control plasmid were used. Engineered urothelial cancer cell lines expressing
each of the Src variants or the EV control were subjected to long-term colony formation assays in the
presence of infigratinib and dasatinib as single agents or in combination. Expression of the gatekeeper
mutant rescued the effects of dasatinib, conferring robust resistance to this drug in all three cell lines
when compared to the WT Src and EV cells (Figure S2B). Collectively, these experiments provide
evidence that low dose dasatinib is highly effective in overcoming intrinsic resistance to selective FGFR
inhibitor treatment in urothelial cancer cell lines expressing FGFR3 molecular alterations and that
dasatinib mediates this effect primarily through blockade of the Src pathway.
3. Discussion
Despite some clinical success with selective FGFR inhibitors in cancers with FGFR3 molecular
alterations, these therapies are not curative and there remains a substantial patient population that
harbour intrinsic resistance to these drugs [13,14]. There is a need to consider new treatment strategies
to tackle intrinsic drug resistance in order to improve long-term outcomes in patients. In this study,
we use a combination of NIH-3T3 and urothelial cancer cells to demonstrate that cells expressing
a subset of FGFR3 molecular alterations co-opt the Src pathway to promote intrinsic resistance to
selective FGFR inhibitors. While cells expressing the FGFR3-TACC3 fusion and extracellular domain
cysteine mutants were resistant to the Src inhibitor dasatinib and selective FGFR inhibitor infigratinib
as single agents, the addition of low dose dasatinib profoundly sensitized these cells to selective
FGFR inhibitors. Our data provide preclinical rationale for the use of this drug combination as a
means to either overcome intrinsic drug resistance to FGFR inhibitors in the salvage therapy setting or
as an upfront strategy to achieve durable drug responses in urothelial cancer patients with FGFR3
molecular alterations.
Preclinical and clinical studies have shed light on some of the mechanisms of resistance to
selective FGFR inhibitors. These are broadly divided into on-target and bypass mechanisms. While
on-target resistance mutations in the FGFR2 kinase domain (N649H/K, V564F, E656A, L617V, K641R
and K659M) have been detected in circulating tumour DNA in the context of FGFR2 translocations
in cholangiocarcinoma patients who have received infigratinib [32,33], such mutations have yet
to be identified in cancers with FGFR3 molecular alterations. Preclinical studies have shown that
upregulation of the AKT pathway as well as ligand-mediated activation of ErbB2/3 are bypass signalling
pathways in the context of acquired resistance to infigratinib in the RT112M cell line [34,35]. In the
paradigm of intrinsic resistance, Herrera-Abreu et al., has shown that EGFR activation is an escape
mechanism to PD173074 treatment and that a combination of gefitinib and PD173074 could overcome
drug resistance in urothelial cancer lines harbouring FGFR3 molecular alterations [22]. Our study
defines Src as a new bypass pathway by which urothelial cancer cells achieve intrinsic resistance to
selective FGFR inhibitors. We further demonstrate that in the urothelial cancer models examined,
Src is not an effector of the EGFR-mediated mechanism previously described by Herrera-Abreu et al.,
but rather a parallel resistance pathway that is independent of EGFR signalling. To our knowledge,
our report is the first description of the use of Src inhibitors such as dasatinib as a means to overcome
intrinsic resistance to selective FGFR inhibitors in cancers with FGFR3 molecular alterations.
Dasatinib has been previously evaluated as a monotherapy in urothelial carcinoma. RT4 cells, which
expresses a different form of the FGFR3-TACC3 fusion employed in this study, are sensitive to treatment
with dasatinib both in vitro and in vivo [36]. Interestingly, it has been shown in another study that genetic
silencing of Src in RT4 cells promotes cancer cell migration and invasion [37]. Dasatinib has been clinically
evaluated in the neoadjuvant setting in muscle-invasive urothelial carcinoma [38]. This phase II trial
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showed that while treatment with this drug led to an on-target decrease in the phosphorylation of Src,
there was no clinical benefit as reflected by the lack significant changes in proliferation and apoptosis
markers in pre- and post-treatment tumours [38]. Our data show that expression of FGFR3-TACC3 and
S249C results in a paradoxical resistance to dasatinib despite the constitutive activation of the Src pathway,
reinforcing the idea that this drug as a monotherapy is likely to be ineffective in cancers with these
FGFR3 molecular alterations. One of the primary ways to address intrinsic drug resistance is the use of
combination therapies that abrogate compensatory survival mechanisms [26,39]. We find that co-targeting
FGFR3 and Src with low nanomolar concentrations of infigratinib and dasatinib respectively is highly
effective in reducing cell viability in urothelial cancer cell lines. This drug combination simultaneously
abrogates Erk1/2 and Src phosphorylation leading to durable efficacy in long term-colony formation
assays, suggesting that simultaneous blockade of these parallel survival pathways is necessary to kill
these cells. The use of Src inhibitors such as dasatinib to overcome resistance to kinase inhibitors has
previously been investigated in the context of mutant EGFR lung cancer [40,41]. A phase I clinical trial
of dasatinib in combination with the EGFR inhibitor erlotinib in advanced non-small-cell lung cancer
showed that the combination is tolerable with disease control in a subset of patients [42]. The clinical
experience in lung cancer suggests that it is feasible to evaluate the efficacy of dasatinib in combination
with selective FGFR inhibitors in patients with FGFR3 molecular alterations.
There remain several outstanding questions. For instance, the mechanisms by which Src blockade
sensitizes cells to FGFR3 inhibition are poorly understood. Since expression of the FGFR3-TACC3
fusion and the substitution of extracellular domain cysteines in FGFR3 confers resistance to dasatinib
as a single agent, it is tempting to speculate a mechanism whereby dasatinib treatment alone has no
therapeutic effect, while the addition of a selective FGFR inhibitor induces a new dependency to the
Src pathway leading to vulnerability to co-treatment with dasatinib. Such induced collateral sensitivity
has been observed with other tyrosine kinase inhibitors [43,44]. There is also a need to investigate the
efficacy of this combination beyond the small panel of FGFR3 molecular alterations examined in this
study in order to establish the generality of these findings and expand its utility to patients harbouring
other FGFR3 mutations. Furthermore, it remains unclear why some FGFR3 aberrations (FGFR3-TACC3
and cysteine mutants) induce resistance to single agent dasatinib while others (N542K and K652E)
do not. It should be noted that the upstream tyrosine kinase pathways responsible for activating Src
are unknown. Similarly, the downstream effectors of Src that drive the sensitization phenotype in the
combination arm have not been investigated. Future studies incorporating global methodologies such
as phosphoproteomics may shed light on the kinase pathways that regulate Src effector function and
dasatinib resistance in urothelial cancer cells [45]. Finally, this study did not investigate the relevance
of Src as a bypass compensatory pathway in the paradigm of acquired resistance to selective FGFR
inhibitors. Future work will seek to determine if blockade of the Src pathway is able to re-sensitise
cells in this acquired resistance context and achieve durable drug responses.
In summary, we show that consistent with the clinical experience, cells bearing a subset of
FGFR3 molecular alterations are intrinsically resistant to selective FGFR inhibitors. Expression of
FGFR3-TACC3 and FGFR3 cysteine point mutants led to constitutive Src activation which can be
exploited for therapy with the Src inhibitor dasatinib. Treatment with dasatinib in combination with
selective FGFR inhibitors was highly effective in overcoming intrinsic drug resistance in urothelial
cancer cells via the dual blockade of the Src and Erk1/2 pathways. This study provides proof-of-principle
evidence that supports co-targeting Src and FGFR3 as a therapeutic approach to tackle drug resistance
in the treatment of urothelial cancers with FGFR3 molecular alterations.
4. Methods and Materials
4.1. Cell Lines
NIH-3T3 cells stably expressing WT FGFR3, FGFR3-TACC3, S249C, N542K and K652E) have
previously been described [16,19]. Urothelial cancer cell lines (BFTC905, RT112M, 639V) and were
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kindly provided by Nicholas Turner. The remaining NIH-3T3 FGFR3 mutant expressing cell lines were
generated in-house. BFTC905 and 639V cell lines were maintained in DMEM and RT112M maintained
in RPMI in 10% FBS (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 2mmol/L L
-glutamine. NIH-3T3 cell lines were cultured with DMEM containing 10% FBS. All cell lines stably
transducing expression constructs where supplemented with 100 µg/mL of hygromycin (InvivoGen,
Toulouse, France), except for FGFR3-TACC3 which was supplemented with 800 µg/mL of geneticin
(Sigma-Aldrich; Merck KGaA, Darmstadt, Germany).
4.2. Generation of Plasmids and Stable Cell Lines
FGFR3 point mutations (S249C, S249A, R248C and R248G) were generated using a retroviral
expression vector containing full-length human FGFR3 [46] by site-directed mutagenesis (SDM).
SDM was performed utilising either the QuikChange Lightning SDM Kit (Agilent Technologies, Inc.,
Santa Clara, CA, USA) and the Q5 SDM kit (New England Biolabs, Inc., Ipswich, MA, USA) following
the manufacturer’s instructions (Supplementary methods). Mutations were confirmed by Sanger
Sequencing (Eurofins Genomics, Ebersberg, Germany). Avian Src constructs were obtained from
Addgene and include pBabe-hygro empty vector (1765, Addgene, Inc., Cambridge, MA, USA), wildtype
Src (26983, Addgene, Inc., Cambridge, MA, USA) and gatekeeper mutant Src (SRC-T338I) (26980,
Addgene, Inc., Cambridge, MA, USA). Cell lines generated in-house were produced by retroviral
transduction. Retroviral particles were produced in HEK293T cell line utilising 15 µg of the insert
plasmid, 15 µg of pUMVC (8449, Addgene, Inc., Cambridge, MA, USA) and 1.88 µg of pCMV-VSV-G
(8454, Addgene, Inc., Cambridge, MA, USA) utilising polyethylenimine (PEI) (1 mg/mL, Sigma-Aldrich;
Merck KGaA, Darmstadt, Germany) as transfection reagent. After 4 days of transfection, medium
with retrovirus was harvested. NIH-3T3, BFTC905, RT112M or 639V cell lines were then transduced
with the harvested retroviral medium diluted 1:4 with growth medium together with 8 µg/mL of
polybrene (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). Cells were then selected for 2 weeks
with 200 µg/mL of hygromycin.
4.3. Western Blotting and Antibodies
Cells were grown for 48h in culture and lysed or treated with the indicated inhibitors prior
to lysis in RIPA lysis buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1 % (v/v) NP40, 0.5 % (w/v)
sodium deoxycholate, 0.1 % (w/v) sodium dodecyl sulphate (SDS)) with 1× Halt™ Protease and
Phosphatase Inhibitor Cocktail with EDTA (Pierce; Thermo Fisher Scientific, Inc., Waltham, MA,
USA). Protein samples were prepared in 4× NuPAGE LDS Sample Buffer (Thermo Fisher Scientific,
Inc., Waltham, MA, USA) and 10× NuPAGE Sample Reducing Agent (Thermo Fisher Scientific, Inc.,
Waltham, MA, USA) and boiled at 95 ◦C for 5 min. When analysing non-reducing samples, the
sample reducing agent was not added to the preparation and the samples were not boiled, but the
subsequent steps of the protocol remained the same. Proteins were resolved on a 4%–12% gradient
gel (Novex; Thermo Fisher Scientific, Inc., Waltham, MA, USA), and transferred onto polyvinylidene
fluoride (PVDF) membranes by dry transfer. Membranes were blocked and incubated with the primary
and secondary HRP-conjugated antibodies in a solution with 5% (w/v) bovine serum albumin (BSA)
(Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) in Tris-buffered saline solution with 0.01% (v/v)
Tween (TBS-T). Antibodies used were: FGFR3 (sc-13121) 1:500 (Santa Cruz Biotechnology; , Inc., Dallas,
TX, USA); FGFR3 (4574) 1:1000, phospho-Y1000 (8954) 1:2000, phospho-Src Y416 (2101) 1:500, Src (2108)
1:1000, phospho-Akt S473 (4058) 1:250–1:500, Akt (4691) 1:1000–1:2000, phospho-Erk1/2 T202/Y404
(4370) 1:2000 and Erk1/1 (4695) 1:2000–1:5000 (all from Cell Signaling Technology, Inc., Danvers, MA,
USA); and Tubulin (T5168) 1:10,000 (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). Anti-rabbit
HRP (7074) 1:2000–1:10,000 (Cell Signaling Technology, Inc., Danvers, MA, USA) and anti-mouse
HRP (G32-62G-1000) 1:10,000 (SignalChem Biotech Inc., Richmond, BC, Canada). Membranes were
developed with Supersignal™ West Pico PLUS Chemiluminescent Substrate (Pierce; Thermo Fisher
Scientific, Inc., Waltham, MA, USA).
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4.4. Anchorage Independent Cell Growth in Soft Agar
To evaluate growth in soft agar, cells were seeded at a density of 20,000 cells/well (in 6-well plates),
in a solution containing 0.35% (w/v) Noble Agar (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany)
in DMEM supplemented with 10% FBS. This was layered over a 0.3% (w/v) agar solution in DMEM also
supplemented with 10% FBS. Plates were incubated for 3 weeks with regular media change. Colonies
were stained with Giemsa Stain Modified Solution (48900; Sigma-Aldrich; Merck KGaA, Darmstadt,
Germany) with 1 part Giemsa to 5 parts glycerol:methanol (5:24 parts). Colonies with a diameter
greater than 10 pixels were analysed on ImageJ software (Java 1.8.0; National Institutes of Health,
Bethesda, MD, USA).
4.5. Colony Formation Assay
Cell growth in the presence of selected inhibitors was evaluated by colony formation assays,
where cells were seeded at a density of 1000 cells/well (in 6-well plates) for 24 h, followed by addition
of relevant drug treatment at the indicated concentrations. Fresh medium with drug was added twice
a week for 14 days. Colonies were fixed with Carnoy’s solution (1 acetic acid: 3 methanol) and stained
with 1% (w/v) crystal violet (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). The percentage of
colonies covering the plates were calculated with ImageJ software.
4.6. Cell Viability Assay and Small Molecule Inhibitor Screen
NIH-3T3 cells were seeded at a density of 1000 cells/well and the urothelial cancer cells lines
were seeded at a density of 3000 cells/well in a 96-well plate format. After 24 h in culture, cells
were treated with the selected inhibitors at the indicated concentrations (5 nM up to 50 µM) for
a further 72 h. Cell viability was assessed with the CellTitre-Glo (CTG) (Promega Corporation,
Madison, WI, USA) reagent, as per the manufacturer’s guidelines. After evaluation of cell viability
by luminescence, values were normalised against the DMSO vehicle control and plotted with a
four-parameter non-linear regression on GraphPad Prism 8 (version 8; GraphPad Software Inc.,
La Jolla, CA, USA), where the half maximal inhibitory concentration (IC50) was calculated. In addition,
to establish synergy in combination arms, the combination index (CI) was calculated according to the
Chou-Talalay method [47]. Cell viability for the small molecule inhibitor screen was also assessed with
the CTG assay utilising a pre-made inhibitor library plate prepared in-house. Small molecule chemical
compounds utilised: AZD4547 (A-1088), BEZ235 (N-4288), NVP-AUY922 (N-5300), Binimetinib
(B-2332), Bosutinib (B-1788), Pazopanib (P-6706), Cediranib (C-4300), Crizotinib (C-7900), Ponatinib
(P-7022), Dasatinib (D-3307), Foretinib (F-4185), Gefitinib (G-4408), Sorafenib (S-8599), Imatinib (I-5577),
Sunitinib (S-8877), Trametinib (T-8123), Lenvatinib (L-5400), Vandetanib (V-9402), all purchased from
LC Laboratories, Woburn, MA, USA. MK-8776 (S2735), AZD5363 (S8019), Momelotinib (S2219), BGJ398
(S2183), NVP-TAE684 (S1108), Palbociclib (S1116), PD173074 (S1264), Ceritinib (S7083), PF562271
(S2890), Dabrafenib (S2807), GSK126 (S7061), Saracatinib (S1006), Silmitasertib (S2248), JQ1 (S7110),
MK2206 (S1078), all purchased from Stratech Scientific Ltd., Ely, UK. MRT67307 (SML0702), BX-795
(SML0694), both purchased from Sigma-Aldrich, Merck KGaA, Darmstadt, Germany.
4.7. Statistical Analysis
Statistical analysis was performed on GraphPad Prism 8 (version 8; GraphPad Software Inc.,
La Jolla, CA, USA) statistical software with one-way or two-way ANOVA with multiple comparisons
tests. Data are presented as mean ± standard deviation (SD). The threshold for statistical significance
was set to * p < 0.05, ** p < 0.01, or *** p < 0.001.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/9/3214/s1.
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